Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
Bronchioloalveolar carcinoma (BAC) and adenocarcinoma mixed subtype with bronchioloalveolar features (ADC-WBF) represent a unique anatomo-clinical entity accounting for some 20% of non-small cell lung cancers (NSCLC). These tumors seem less sensitive to chemotherapy than other NSCLC. We report two cases of advanced ADC-WBF treated with second-line and fourth-line pemetrexed. Major and durable radiological response associated with clinical and functional improvement was achieved in both patients, without important drug toxicity. After treatment arrest, the two patients experienced progressive disease but responded to retreatment with pemetrexed. Recent data suggest that paclitaxel-based chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors could be an acceptable therapeutic strategy in unresectable CBA and ADC-WBF. The cases reported here and preclinical findings suggest a therapeutic efficacy of pemetrexed in these tumors. Prospective studies are required to evaluate this hypothesis.
Duruisseaux
Michaël
M
Service de Pneumologie, Unité d'Oncologie Thoracique, Hôpital de la Croix Rousse, Lyon Cedex, France.
Cadranel
Jacques
J
Biron
Elisabeth
E
Pérol
Maurice
M
Guérin
Jean Claude
JC
Arpin
Dominique
D
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000556:secondary*; D003371:Cough; D018450:Disease Progression; D004417:Dyspnea; D005492:Folic Acid / Q000008:administration & dosage; D005971:Glutamates / Q000009:adverse effects / Q000627:therapeutic use*; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D009367:Neoplasm Staging; D009503:Neutropenia; D000068437:Pemetrexed; D012074:Remission Induction; D051437:Renal Insufficiency; D012907:Smoking; D014057:Tomography, X-Ray Computed; D014805:Vitamin B 12 / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D005492:Folic Acid; D014805:Vitamin B 12